- Fee assured
- Verified this account
- Impotency and infertility
- Urological malignancy
Born in Basingstoke, Hampshire, I was educated at The Vyne School and Queen Marys College before going onto study at the School of Medicine at The University of Manchester. Here I obtained a 1st Class Honours degree in Anatomy followed by my primary medical degree (MB.ChB.). After gaining my Fellowship of the Royal College of Surgeons I undertook a period of research at the Cancer Research UK Laboratories (Paterson Institute for Cancer Research/Christie Hospital) in Manchester. Here I undertook research in the treatment of bladder cancer, which led to the award of a Doctorate of Medicine (MD). I subsequently trained in General Urology in the North West of England and then undertook specialist training in Urological Cancer management at the Christie Hospital during which I obtained my Certificate of Specialist Training and my Specialist Urological Fellowship of The Royal College of Surgeons. In addition to this I spent a short period working at the Royal Surrey County Hospital learning Minimally Invasive Surgery and also attended the University Louis Pastuer, Strasburg, France , where I obtained a Diploma in Laparoscopic Surgery. I then took up my post as Consultant Urological Surgeon/Urologist at The Christie Hospital and University Hospital of South Manchester.
I specialise in Penile surgery with some reconstructive work, having the largest penile practice in the north of England; my work also involves dealing with Sexual Dysfunction. This has led to the development of an interest in Male Infertility Surgery using modern techniques. I also manage Testis, Bladder, Kidney and Prostate problems including Cancer,; I have developed a specialist interest in New Technologies for the treatment of some of these conditions.
I am active in research, having published in journals and presented my research internationally.
Areas of interest
Mens Health; Bladder Cancer; Prostate Cancer; Raised PSA; Blood in Urine; Bladder syndromes; Fertility / infertility and assisted conception; Circumcision; Penile disorders; Penile surgery; Penile cancer; Peyronies; circumcision; redo circumcision; Shock wave therapy; Bladder cancer; Erectile dysfunction; Vasectomy (including reversal); Inguinal scrotal disorders; Andrology; Bladder; Incontinence (urine); Kidney (renal) cancer; Prostate disease including prostate cancer; Urological oncology; hypogonadism
Anaesthetists worked with
- Dr Nirendra Jena Fee Assured
Current NHS consultant posts held
Christie Hospital NHS Trust
Manchester University NHS Foundation Trust
Bladder and prostate cancer
Swimming, cooking, travel
European Association of Urology Congress Best Poster Presentation Paris, France. 2002, 2005, 2007.
BUF Clinical Visit Fellowship to The Netherlands Cancer Institute, Amsterdam Jan 2007.
Global Lilly Young Investigators Translational/Pharmacogenomics Research Award.
AACR-NCI-EORTC International Conference. Molecular Targets and Cancer Therapeutics: Discovery, Biology and Clinical Applications. Astra Zeneca Best Poster Prize. October 2001.
Phase II study of conformal hypofractionated radiotherapy withconcurrent gemcitabine in muscle-invasive bladder cancer. J Clin Oncol. 2011 Feb
2: Management of the lymph nodes in penile cancer. Urology. 2010 Aug;76(2 Suppl
3: sufferers: a systematic review of the quality of life, psychosexual and psychosocial literature in penile cancer. BMC Urol. 2009 Aug 8;9:8.
4: Imaging in primary penile cancer: current
status and future directions. Eur Radiol. 2010 Jan;20(1):36-47. Epub 2009 Aug 6.
5: Should molecular technology replace urinecytology? BJU Int. 2008 Nov;102(10):1361.
6: Histologicaloutcome of delayed orchidectomy after primary chemotherapy for metastatic germcell tumour of the testis. Clin Oncol (R Coll Radiol). 2008 Apr;20(3):247-52.Epub 2008 Feb 21.
7: A 15-year longitudinal analysis of trends inelective urological surgery - an evidence base for Modernising Medical Careers.Ann R Coll Surg Engl. 2007 Mar;89(2):157-61.
8: Sperm retrievalrates in subgroups of primary azoospermic males. Eur Urol. 2007 Feb;51(2):534-9; discussion 539-40.
9:Phase I study of conformal radiotherapy with concurrent gemcitabine inlocally advanced bladder cancer. Int J Radiat Oncol Biol Phys. 2005 Feb1;61(2):420-5.
10: Is DRE essential for the follow up of prostate cancer patients? A prospectiveaudit of 194 patients. BMC Urol. 2005 Jan 10;5:1. PubMed PMID: 15642124;
11: The economicconsequences of prostate and bladder cancer in the UK. BJU Int. 2005
12: Differentialradiosensitisation by ZD1839 (Iressa), a highly selective epidermal growth factorreceptor tyrosine kinase inhibitor in two related bladder cancer cell lines. Br JCancer. 2005 Jan 17;92(1):125-30. PubMed PMID: 15611794;
13: An evaluation ofgemcitabines differential radiosensitising effect in related bladder cancer cell
lines. Br J Cancer. 2004 Jan 26;90(2):542-8. PubMed
Courses offered to GPs
Please ask via my secretary on 0161 447 6764
Re-admission rate less than 1%
Mortality rate less than 1%
Patient satisfaction over 90%
Post op MRSA rate 0%
These are based on all procedures across two operating sites and are an amalgamation of personal and CLIP data.
- MBChB Manchester 1993
- MD Manchester 2005
- FRCS (Urol) Royal College 2005
Reference number 4013107
Professional bodies (positions held - last 3 yrs)
- Executive Committee Member Section of Andrology British Association of Urological Surgeons 2012
- Member Penile Cancer Subgroup National Cancer Research Insititute 2012
Details of entry to specialist register
- Urology, 2007
Affiliations / memberships
European Association of Urology
British Assoc of Urology
Societe Internationale d'Urologie
Post treatment communication
Following treatment of a Bupa member, I will communicate with GPs in line with Department of Health, GMC and appropriate professional bodies guidelines.
In the event of an urgent query following treatment, Bupa members should use the following contact details
0161 447 6764